Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 7/3067% above fair value
$3.45−0.07 (-1.99%)
Close on Nov 13, 2026Market cap $275.32MP/E –Yield –
Prelude Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Prelude Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $69.43M, down 40.0% year over year. For fiscal 2025 it was $94.30M, down 20.1% from the year before. The highest annual figure on record is $118.00M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.30M | -20.1% |
| FY2024 | Dec 31, 2024 | $118.00M | +14.1% |
| FY2023 | Dec 31, 2023 | $103.39M | +11.3% |
| FY2022 | Dec 31, 2022 | $92.89M | +7.0% |
| FY2021 | Dec 31, 2021 | $86.78M | +80.1% |
| FY2020 | Dec 31, 2020 | $48.18M | +98.4% |
| FY2019 | Dec 31, 2019 | $24.28M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.13M | -37.4% |
| Q1 FY2026 | Mar 31, 2026 | $13.60M | -52.8% |
| Q4 FY2025 | Dec 31, 2025 | $17.99M | -43.1% |
| Q3 FY2025 | Sep 30, 2025 | $21.71M | -26.3% |
| Q2 FY2025 | Jun 30, 2025 | $25.78M | -12.6% |
| Q1 FY2025 | Mar 31, 2025 | $28.82M | +5.1% |
| Q4 FY2024 | Dec 31, 2024 | $31.62M | +4.2% |
| Q3 FY2024 | Sep 30, 2024 | $29.46M | +12.2% |
| Q2 FY2024 | Jun 30, 2024 | $29.51M | +18.2% |
| Q1 FY2024 | Mar 31, 2024 | $27.41M | +25.5% |
| Q4 FY2023 | Dec 31, 2023 | $30.33M | +17.3% |
| Q3 FY2023 | Sep 30, 2023 | $26.26M | +14.7% |
| Q2 FY2023 | Jun 30, 2023 | $24.97M | +17.2% |
| Q1 FY2023 | Mar 31, 2023 | $21.83M | -4.3% |
| Q4 FY2022 | Dec 31, 2022 | $25.87M | +2.7% |
| Q3 FY2022 | Sep 30, 2022 | $22.89M | +0.7% |
| Q2 FY2022 | Jun 30, 2022 | $21.31M | -4.9% |
| Q1 FY2022 | Mar 31, 2022 | $22.82M | +38.6% |
| Q4 FY2021 | Dec 31, 2021 | $25.18M | +72.8% |
| Q3 FY2021 | Sep 30, 2021 | $22.72M | +48.6% |
| Q2 FY2021 | Jun 30, 2021 | $22.41M | +129.2% |
| Q1 FY2021 | Mar 31, 2021 | $16.47M | +92.9% |
| Q4 FY2020 | Dec 31, 2020 | $14.57M | +64.7% |
| Q3 FY2020 | Sep 30, 2020 | $15.29M | +178.6% |
| Q2 FY2020 | Jun 30, 2020 | $9.78M | – |
| Q1 FY2020 | Mar 31, 2020 | $8.54M | – |
| Q4 FY2019 | Dec 31, 2019 | $8.85M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.49M | – |
See a number that looks wrong?